



(51) International Patent Classification:

A61K 47/48 (2006.01) *G01N 30/06* (2006.01)
A61K 39/095 (2006.01) *G01N 30/96* (2006.01)
A61P 31/04 (2006.01)

(21) International Application Number:

PCT/EP2013/060447

(22) International Filing Date:

22 May 2013 (22.05.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/650,025 22 May 2012 (22.05.2012) US
 61/698,677 9 September 2012 (09.09.2012) US
 61/799,528 15 March 2013 (15.03.2013) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
CH-4056 Basel (CH).

(72) Inventors: **ROMANO, Maria Rosaria**; Novartis Vaccines
and Diagnostics SrL, Via Fiorentina 1, I-53100 Siena (IT).
MICOLI, Francesca; Novartis Vaccines Institute for
Global Health, Via Fiorentina 1, I-53100 Siena (IT).
BERTI, Francesco; Novartis Vaccines and Diagnostics
SrL, Via Fiorentina 1, I-53100 Siena (IT). **ADAMO,**
Roberto; Novartis Vaccines and Diagnostics SrL, Via
Fiorentina 1, I-53100 Siena (IT). **COSTANTINO, Paolo**;
 Novartis Vaccines and Diagnostics SrL, Via Fiorentina 1,
 I-53100 Siena (IT).

(74) Agents: **EVANS, Stephen John Eves** et al.; Novartis Vac-
cines and Diagnostics S.r.L., Via Fiorentina 1, I-53100 Si-
ena (IT).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MENINGOCOCCUS SEROGROUP X CONJUGATE

(57) Abstract: The invention provides a conjugate of a *Neisseria meningitidis* serogroup X capsular polysaccharide and a carrier molecule. The conjugate is typically made by (a) oxidising a primary hydroxyl group in the capsular polysaccharide, to give an oxidised polysaccharide with an aldehyde group; and (b) coupling the oxidised polysaccharide to a carrier molecule via the aldehyde group, thereby giving the conjugate. The conjugate may be part of an immunogenic composition. This composition may comprise one or more further antigens, particularly capsular polysaccharides from serogroups A, W135, C and Y and conjugated forms thereof. The composition may be in an aqueous formulation. The composition is useful as a vaccine, e.g. for raising an immune response in a mammal. The invention also provides processes for making the conjugate.

